All In Biotech

Drug Trial Radar · NCT03257267

Study of Cemiplimab in Adults With Cervical Cancer

An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma

Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 608 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

608

Actual

Start

Sep 5, 2017

Primary completion

Mar 15, 2021

Study completion Apr 20, 2023

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Aug 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic cervical cancer who have histology of squamous cell carcinoma (SCC) and who have any eligible histology treated with either cemiplimab or investigator's choice (IC) chemotherapy. The secondary objectives performed among SCC patients and among all eligible histologies (SCC and adenocarcinoma/adenosquamous carcinoma (AC) are: * To compare progression-free survival (PFS) of cemiplimab versus IC chemotherapy * To compare objective response rate (ORR) (partial response \[PR\] + complete response \[CR\]) of cemiplimab versus IC chemotherapy per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * To compare the duration of response (DOR) of cemiplimab versus IC chemotherapy * To compare the safety profiles of cemiplimab versus IC chemotherapy by describing adverse events (AE) * To compare quality of life (QOL) for patients treated with cemiplimab versus IC chemotherapy using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

Conditions

  • Squamous Cell Carcinoma (SCC)
  • Recurrent or Metastatic, Platinum-refractory Cervical Cancer

Interventions

  • CemiplimabDrug

    Intravenous (IV) administration every 3 weeks (Q3W)

  • Investigator Choice (IC) ChemotherapyDrug

    IC chemotherapy options include: 1. Antifolate: Pemetrexed 2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan 3. Nucleoside analogue: Gemcitabine 4. Vinca alkaloid: Vinorelbine The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From first dose up to 90 following last dose (~42 months)
  2. Overall Survival (OS) in the SCC PopulationTime frame: From first dose up to 90 following last dose (~42 months)

Locations

105 sites in 14 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates

    Phoenix, Arizona

  • Arizona Oncology Associates

    Tucson, Arizona

  • University of California Irvine

    Orange, California

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Cancer Research for the Ozarks

    Springfield, Missouri

  • New York Presbyterian Queens

    Flushing, New York

  • Northwell Health

    Lake Success, New York

  • Laura and Issac Perlmutter Cancer Center at NYU Langone

    New York, New York

  • First Health of the Carolinas Outpatient Cancer Center

    Pinehurst, North Carolina

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Texas Oncology, P.A.

    Austin, Texas

  • St. George Hospital

    Kogarah, New South Wales, Australia

  • Northern NSW Health District, The Tweed Hospital

    Tweed Heads, New South Wales, Australia

  • Royal Brisbane & Women's Hospital

    Herston, Queensland, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • St. John of God Subiaco Hospital

    Subiaco, Western Australia, Australia

  • OLV ziekenhuis Aalst, Medische oncologie- Radiotherapie

    Aalst, Belgium

  • Institut Bordet

    Brussels, Belgium

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium

  • UZLeuven Gynaelologic Oncology

    Leuven, Belgium

  • CHC Saint Joseph

    Liège, Belgium

  • CHU Liège

    Liège, Belgium

  • CHU UCL Namur site Sainte Elisabeth

    Namur, Belgium

  • Instituto de Pesquisas Clinicas para Estudos Multicentricos - IPCEM

    Caxias do Sul, Brazil

  • Instituto Nacional de Cancer - INCA

    Rio de Janeiro, Brazil

  • Instituto COI de Pesquisa

    Rio de Janeiro, Brazil

  • Liga Norte Riograndense Contra o Câncer

    Natal, Rio Grande do Norte, Brazil

  • Hosptial Sao Lucas da PUC de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro de Novos Tratamentos Itajai

    Itajaí, Santa Catarina, Brazil

  • Fundação Pio XII - Hospital de Câncer de Barretos

    Barretos, São Paulo, Brazil

  • Tom Baker Cancer Center

    Calgary, Alberta, Canada

  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Hospital Maisonneuve-Rosemont

    Montreal, Quebec, Canada

  • Hopital Notre-Dame du Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • General Hospital of Athens Alexandra

    Athens, Greece

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.